SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) has discontinued the Phase II/III clinical trial of Troxatyl™ as a third-line treatment for patients suffering from acute myelogenous leukemia (AML).
The discontinuation of the said trial is based upon the recommendation of the study's independent data and safety monitoring board (DSMB) which found that the study response rates were unlikely to provide evidence of a treatment benefit as a third-line treatment for patients with AML and not due to safety concerns.
According to Mike Grey, president and chief executive officer of SGX Pharmaceuticals:
"The response rates observed to date in our Phase II/III trial of Troxatyl are not at a level that we believe would support a New Drug Application as a third-line treatment for AML and we feel it is appropriate to follow the recommendation of the DSMB to discontinue this trial.
Although we are disappointed with the results of Troxatyl in this very difficult to treat third-line AML population, Troxatyl has produced interesting clinical results in other indications and we remain optimistic for its potential in these other indications.
We will now analyze data from all patients treated thus far in the Phase II/III trial and will be taking a careful look at the range of opportunities to determine an appropriate development path for Troxatyl."
In spite of this, SGX Pharmaceuticals remain enthusiastic about the company’s pipeline and proprietary drug discovery platform, FAST™.
Read the full press release.
Comment Preview